106 related articles for article (PubMed ID: 904743)
1. VM 26 (4-demethyl-epipodophyllotoxin-beta-d-thenylidine glucoside) in the treatment of urinary bladder tumors.
Mechl Z; Rovný F; Sopková B
Neoplasma; 1977; 24(4):411-4. PubMed ID: 904743
[TBL] [Abstract][Full Text] [Related]
2. Preliminary evaluation of VM-26: a new epipodophyllotoxin derivative, in the treatment of urogenital tumours.
Pavone-Macaluso M; Caramia G; Rizzo FP; Messana V
Eur Urol; 1975; 1(1):53-6. PubMed ID: 786645
[TBL] [Abstract][Full Text] [Related]
3. EORTC randomized trial for the adjuvant therapy of T1 bladder carcinoma.
Schulman CC; Rozencweig M; Staquet M; Kenis Y; Sylvester R
Eur Urol; 1976; 2(6):271-3. PubMed ID: 829223
[TBL] [Abstract][Full Text] [Related]
4. [The toxicity of massive dosis of VM26 (4-demethyl-epipodophyllotoxin-beta-D-thenylidene glucoside). A contribution to the therapy of advanced ovarian cancer (author's transl)].
Jankowski RP; Vahrson H
Med Klin; 1977 Dec; 72(49):2122-6. PubMed ID: 337083
[TBL] [Abstract][Full Text] [Related]
5. [Use of VM-26 as a single agent in the treatment of transitional cell carcinoma of the urinary tract].
Aso Y; Ushiyama T; Suzuki K; Tajima A; Naide Y; Ohshima S; Matsuura O; Fukushima M; Ota K; Ono Y
Nihon Gan Chiryo Gakkai Shi; 1988 May; 23(5):1046-51. PubMed ID: 3418215
[No Abstract] [Full Text] [Related]
6. Chemotherapeutic management of carcinoma of the bilharzial bladder: a phase II trial with hexamethylmelamine and VM-26.
Gad-el-Mawla NM; Muggia FM; Hamza MR; El-Morsi B; Sherif M; Mansour MA; Khafagy M; El-Sebai IT
Cancer Treat Rep; 1978 Jul; 62(7):993-6. PubMed ID: 99234
[No Abstract] [Full Text] [Related]
7. Comparison of uptake and binding of two epipodophyllotoxin glucopyranosides, 4'-demethyl epipodophyllotoxin thenylidene-beta-D-glucoside and 4'-demethyl epipodophyllotoxin ethylidene-beta-D-glucoside, in the L1210 leukemia cell.
Allen LM
Cancer Res; 1978 Aug; 38(8):2549-54. PubMed ID: 667850
[No Abstract] [Full Text] [Related]
8. Combination VM-26 and adriamycin for metastatic transitional cell carcinoma.
Rodriguez LH; Johnson DE; Holoye PY; Samuels ML
Cancer Treat Rep; 1977; 61(1):87-8. PubMed ID: 324624
[No Abstract] [Full Text] [Related]
9. Teniposide in metastatic renal and bladder cancer: a Southwest Oncology Group Study.
Oishi N; Berenberg J; Blumenstein BA; Johnson K; Rivkin SE; Bukowski RM; O'Bryan RM; Stephens RL; Quagliana J; Saiers JH
Cancer Treat Rep; 1987 Dec; 71(12):1307-8. PubMed ID: 3690547
[No Abstract] [Full Text] [Related]
10. [New antineoplastic drugs of the podophyllotoxin derivative group].
Robak T; Płuzańska A
Pol Tyg Lek; 1983 Jan; 38(1):27-30. PubMed ID: 6346283
[No Abstract] [Full Text] [Related]
11. 4'-Demethylepipodophyllotoxin-beta-D-glucoside: a new podophyllotoxin derivative with VM-26-like and VP-16-213-like activities.
Gupta RS; Singh B
J Natl Cancer Inst; 1984 Jul; 73(1):241-8. PubMed ID: 6588229
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant therapy of T1 bladder carcinoma: preliminary results of an EORTC randomized study.
Schulman C; Sylvester R; Robinson M; Smith P; Lachand A; Denis L; Pavone-Macaluso M; De Pauw M; Staquet M
Recent Results Cancer Res; 1978; 68():338-45. PubMed ID: 111322
[TBL] [Abstract][Full Text] [Related]
13. Epipodophyllotoxin VM-26 in the treatment of childhood neuroblastoma.
Rivera G; Green A; Hayes A; Avery T; Pratt C
Cancer Treat Rep; 1977 Oct; 61(7):1243-8. PubMed ID: 589594
[TBL] [Abstract][Full Text] [Related]
14. 4'-demethyl-epipodophyllotoxin-beta-D-thenylidene glucoside (VM-26)--a brief review.
Goldsmith MA; Carter SK
Eur J Cancer (1965); 1973 Jul; 9(7):477-82. PubMed ID: 4609765
[No Abstract] [Full Text] [Related]
15. Structure-activity study of the inhibition of microtubule assembly in vitro by podophyllotoxin and its congeners.
Loike JD; Brewer CF; Sternlicht H; Gensler WJ; Horwitz SB
Cancer Res; 1978 Sep; 38(9):2688-93. PubMed ID: 679171
[TBL] [Abstract][Full Text] [Related]
16. A quantitative microdensitometric and autoradiographic study of the effect of 4'-demethyl-epipodophyllotoxin-beta-D-thenylidene glucoside (VM-26) on the cell cycle of cultured fibroblasts.
Gotzos V; Cappelli-Gotzos B; Despond JM
Histochem J; 1979 Nov; 11(6):691-707. PubMed ID: 536243
[TBL] [Abstract][Full Text] [Related]
17. [Surgically treated supratentorial gliomas in the adult. Favourable action of a podophyllin derivative (VM 26) administered alone (author's transl)].
Trouillas P; Chassard JL; Tommasi M; Aimard G; Devic M
Nouv Presse Med; 1978 Dec; 7(44):4017-9. PubMed ID: 733569
[TBL] [Abstract][Full Text] [Related]
18. Single-drug chemotherapy of bladder cancer with adriamycin, VM-26 or bleomycin. A phase II multicentric, co-operative study.
Eur Urol; 1976; 2(3):138-41. PubMed ID: 70352
[TBL] [Abstract][Full Text] [Related]
19. Uridine enhances the chemotherapeutic action of the 4'-demethylepipodophyllotoxin-thenylidene-glucoside (VM 26)-cyclophosphamide combination on i.m. implanted Ehrlich carcinoma.
Osswald H
Arzneimittelforschung; 1978; 28(3):387-8. PubMed ID: 580745
[TBL] [Abstract][Full Text] [Related]
20. Nonresponsiveness of brain tumors to VM-26 therapy in children.
Sullivan MP; van Eys J; Herson J; Starling KA; Ragab A; Sexhauer C
Cancer Treat Rep; 1979 Jan; 63(1):155-6. PubMed ID: 369689
[No Abstract] [Full Text] [Related]
[Next] [New Search]
